New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy

Molecular Therapy

Volumn 15, Issue 11, 2007, Pages 1910-1916

  Pike Overzet, Karin ^a   van der Burg, Mirjam ^a   Wagemaker, Gerard ^a   van Dongen, Jacques J M ^a   Staal, Frank J T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; ONCOPROTEIN; PROTEIN KINASE ZAP 70; RAG1 PROTEIN; RAG2 PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; GENE EXPRESSION REGULATION; GENE LOCUS; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; RETROVIRUS; REVIEW; T CELL LEUKEMIA; T LYMPHOCYTE; VIRAL GENE THERAPY; X CHROMOSOME LINKED DISORDER;

MURINAE;

EID: 35549013276     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300297     Document Type: Review

References (56)

1. Du Y, Jenkins, NA and Copeland, NG. (2005). Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932-3939.
2. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knoss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
3. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Dullmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
4. Li, Z, Dullmann, J, Schiedlmeier, B, Schmidt M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
5. Laufs, S, Nagy, KZ, Giordano, FA, Hotz-Wagenblatt A, Zeller, WJ and Fruehauf, S (2004). Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 10: 874-881.
6. Calmels, B, Ferguson, C, Laukkanen, MO, Adler, P, Faulhaber, M, Kim, HJ et al. (2005). Recurrent retroviral vector integration at the Mds1/Evil1 locus in nonhuman primate hematopoietic cells. Blood 106 2530-2533.
7. Hacein-Bey-Abina, S, von Kalle, C, Schmidt M, Le Deist, F, Wutffraat N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
8. Marshall, E (2003). Gene therapy. Second child in French trial is found to have leukemia. Science 299: 320.
9. Check, E (2005). Gene therapy put on hold as third child develops cancer. Nature 433:561.
10. O'Shea, JJ, Pesu, M, Borie, DC and Changelian, PS (2004). A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555-564.
11. Cavazzana-Calvo, M and Fischer, A (2007). Gene therapy for severe combined immunodeficiency: Are we there yet? J Clint Invest 117 1456-1465.
12. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004), Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
13. Hacein-Bey-Abina, S, Fischer, A and Cavazzana-Calvo, M (2002). Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 76: 295-298.
14. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay,JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193.
15. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated cional T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
16. Weerkamp, F, Pike-Overzet, K and Staal, FI (2006). T-sing progenitors to commit. Trends Immunol 27:125-131.
17. Kang, J, Volkmann, A and Raulet, DH (2001). Evidence that γδ versus aβ T cell fate determination is initiated independently of T cell receptor signaling. J Exp Med 193: 689-698.
18. Ciofani, M, Knowles, GC, Wiest, DL, von Boehmer, H and Zuniga-Pflucker, JC (2006). Stage-specific and differential notch dependency at the aβ and γδ T lineage bifurcation. Immunity 25: 105-116.
19. Dik, WA, Pike-Overzet, K, Weerkamp, F, de Ridder, D, de Haas, EF, Baert, MR et al. (2005). New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 201:1715-1723.
20. Allman, D, Sambandam, A, Kim, S, Miller, JP, Pagan, A, Well, D et al. (2003). Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 4:168-174.
21. Weerkamp, F, Baert, MR, Naber, BA, Koster, EE, de Haas, EF, Atkuri, KR et al. (2006). Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc Natl Acad Sci USA 103: 3322-3326.
22. Schwarz, K, Gauss, GH, Ludwig, L, Pannicke, U, Li, Z, Lindner, D et al. (1996). RAG mutations in human B cell-negative SCID. Science 274: 97-99.
23. Villa, A, Sobacchi, C, Notarangelo, LD, Bozzi, F, Abinun, M, Abrahamsen, TG et al. (2001). V(D)J recombination defects in lymphocytes due to RAG mutations: Severe immunodeficiency with a spectrum of clinical presentations. Blood 97: 81-88.
24. Noordzij, JG, de Bruin-Versteeg, S, Verkaik, NS, Vossen, JM, de Groot, R, Bernatowska, E et al. (2002). The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood 100: 2145-2152.
25. Notarangelo, L, Casanova, JL, Conley, ME, Chapel, H, Fischer, A, Puck, J et al. (2006). Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 117: 883-896.
26. + severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 116: 137-145.
27. Recio, MJ, Moreno-Pelayo, MA, Kilic, SS, Guardo, AC, Sanal, O, Allende, LM et al. (2007). Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol 178: 2556-2564.
28. + severe combined immunodeficiency caused by complete deficiency of the CD3ζ subunit of the T-cell antigen receptor complex. Blood 109: 3198-3206.
29. Noordzij, JG, Verkaik, NS, van der Burg, M, van Veelen, LR, de Bruin-Versteeg, S, Wiegant, W et al. (2003). Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood 101: 1446-1452.
30. + severe combined immunodeficiency. Nat Genet 20: 394-397.
31. Peschon, JJ, Morrissey, PJ, Grabstein, KH, Ramsdell, FJ, Maraskovsky, E, Gliniak, BC et al. (1994). Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180: 1955-1960.
32. Wakamiya, M, Blackburn, MR, Jurecic, R, McArthur, MJ, Geske, RS, Cartwright, I Jr. et al. (1995). Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 92: 3673-3677.
33. Migchielsen, AA, Breuer, ML, van Roon, MA, te Riele, H, Zurcher, C, Ossendorp, F et al. (1995). Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 10: 279-287.
34. Blackburn, MR, Datta, SK and Kellems, RE (1998). Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273 5093-5100.
35. + thymic selection in humans lacking zap-70 kinase. Cell 76: 947-958.
36. Royer-Pokora, B, Loos, U and Ludwig, WD (1991). TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6 1887-1893.
37. Boehm, T, Foroni, I, Kaneko, Y, Perutz, MF and Rabbitts, TH (1991). The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 88: 4367-4371.
38. Dik, WA, Nadel, B, Przybylski, GK, Asnafi, V, Grabarczyk, P, Navarro, JM et al. (2007). Different chromosomal breakpoints impact level of LMO2 expression in T-ALL. Blood 110: 388-392.
39. Nam, CH and Rabbitts, TH (2006). The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther 13: 15-25.
40. + cells: implications for leukemogenesis in gene therapy. Leukemia 21 754-763.
41. Larson, RC, Osada, H, Larson, TA, Lavenir, I and Rabbitts TH (1995). The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 11: 853-862.
42. Neale, GA, Rehg, JE and Goorha, RM (1995). Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8-lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood 86: 3060-3071.
43. Dave, UP, Jenkins, NA and Copeland, NG (2004). Gene therapy insertional mutagenesis insights. Science 303: 333.
44. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: Therapeutic gene causing lymphoma. Nature 440: 1123.
45. Pike-Overzet, K, de Ridder, D, Weerkamp, F, Baert, MR, Verstegen, MM, Brugman, MH et al. (2006). Gene therapy: Is IL2RG oncogenic in T-cell development? Nature 443: E5; discussion E6-E7.
46. Thrasher, AJ, Gaspar, HB, Baum, C, Modlich, U, Scharqbach, A, Candotti, F et al. (2006). Gene therapy: X-SCID transgene leukaemogenicity. Nature 443: E5-E6; discussion E6-E7.
47. Foot, AB, Oakhill, A and Kitchen, C (1992). Acute monoblastic leukemia of infancy in Klinefelter's syndrome. Cancer Genet Cytogenet 61 99-100.
48. Lessard, J and Sauvageau, G (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
49. Hussey, DJ, Nicola, M, Moore, S, Peters, GB and Dobrovic, A (1999). The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 94: 2072-2079.
50. Seimiya, M, O-Wang, J, Bahar, R, Kawamura, K, Wang, Y, Saisho, H et al. (2003). Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: Elevated expression in human B lymphomas. Int J Oncol 22: 301-304.
51. Korz, C, Pscherer, A, Benner, A, Mertens, D, Schaffner, C, Leupolt, E et al. (2002). Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99: 4554-4561.
52. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biaso, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240.
53. Hammond, SM, Crable, SC and Anderson, KP (2005). Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res 29: 89-97.
54. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735.
55. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat biotechnol 24: 687-696.
56. Lagresle-Peyrou, C, Yates, F, Malassis-Seris, M, Hue, C, Morillon, E, Garrigue, A et al. (2006). Long-term immune reconstitution in RAGA-1-deficient mice treated by retroviral gene therapy: A balance between efficiency and toxicity. Blood 107: 63-72.